How Bayer's Engineered Antibodies Help Blood Clotting

This patent describes specific engineered antibodies designed to block a protein that prevents blood clotting, potentially helping people with bleeding disorders.

What it covers

The patent covers a specific type of human monoclonal IgG antibody that binds to a protein called Tissue Factor Pathway Inhibitor (TFPI). TFPI normally acts as a brake on the body's blood-clotting process. By binding to and inhibiting TFPI, these engineered antibodies effectively remove that brake, which can help promote clotting in patients who have deficiencies in their blood coagulation system. The claims specify exact amino acid sequences and precise substitutions (like K55Y or D62R) within the antibody's binding regions (CDRs) to ensure the antibody attaches to TFPI with high specificity.

What it doesn't cover

• —Does not cover naturally occurring antibodies found in the human body.
• —Does not cover antibodies that bind to proteins other than TFPI.
• —Does not cover therapeutic methods that use small-molecule drugs instead of monoclonal antibodies.
• —Does not cover antibodies lacking the specific amino acid substitutions defined in the claims.

The clever bit

The innovation lies in the specific amino acid 'tuning' of the antibody's binding loops (CDRs). By making precise substitutions at key positions, the inventors increased the antibody's affinity for TFPI, making the treatment more potent and effective at lower doses.

Why it matters

This technology is significant for treating hemophilia and other bleeding disorders where the body struggles to form stable clots. By targeting TFPI, these antibodies offer an alternative approach to traditional factor replacement therapies, which require frequent injections. This patent represents a core intellectual property asset for Bayer in the development of potential hemophilia treatments.

Real-world examples

• 1.Experimental hemophilia therapies
• 2.Targeted monoclonal antibody drug candidates for coagulation disorders